Botanical Product Use Among Multiple Myeloma Patients In Commercial Drug Trials

Botanical medication use is frequently reported among patients with cancer, including those undergoing treatment. The use of botanical medicines among patients with solid tumors has been frequently studied and concerns raised about the potential for botanical-drug interactions. To date, limited information exists about botanical medicine use for multiple myeloma patients. Furthermore, relatively few studies of botanical medicine use among cancer patients enrolled in commercial clinical trials have been undertaken, despite the importance of these trials for establishing the safety and efficacy of new drugs. We sought to describe botanical concomitant medication use among patients with multiple myeloma enrolled on commercial trials of anti-myeloma investigational products, the content of trial protocols regarding concomitant botanical medications, and the potential for botanical-drug interactions.